Through Kaplan-Meier survival analysis, we found that high TRPML2 expression was strongly correlated with short OS (11 months), whereas low TRPML2 expression was associated with a more favorable OS (33 months) in GBM patients, suggesting that TRPML2 mRNA overexpression represents a negative prognostic factor in GBM patients. The gene discussed is MCOLN2; the disease is glioblastoma.